Chinese bribery crackdown far from over for pharma
This article was originally published in SRA
While things may appear to have gone quiet regarding the bribery probes in the Chinese pharma sector, the reality is that the government and provincial authorities are continuing to crack down and will do so for years yet.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.